Tumor	0	5	B-Pathological_formation
Angiogenesis	6	18	O
:	18	19	O
Initiation	20	30	O
and	31	34	O
Targeting	35	44	O
-	45	46	O
Therapeutic	47	58	O
Targeting	59	68	O
of	69	71	O
an	72	74	O
FGF	75	78	B-Gene_or_gene_product
-	78	79	I-Gene_or_gene_product
Binding	79	86	I-Gene_or_gene_product
Protein	87	94	I-Gene_or_gene_product
,	94	95	O
an	96	98	O
Angiogenic	99	109	O
Switch	110	116	O
Molecule	117	125	O
,	125	126	O
and	127	130	O
Indicator	131	140	O
of	141	143	O
Early	144	149	O
Stages	150	156	O
of	157	159	O
Gastrointestinal	160	176	B-Pathological_formation
Adenocarcinomas	177	192	I-Pathological_formation
-	193	194	O
.	194	195	O

Tumor	197	202	B-Pathological_formation
angiogenesis	203	215	O
has	216	219	O
been	220	224	O
related	225	232	O
to	233	235	O
the	236	239	O
initiation	240	250	O
as	251	253	O
well	254	258	O
as	259	261	O
progression	262	273	O
toward	274	280	O
more	281	285	O
aggressive	286	296	O
behavior	297	305	O
of	306	308	O
human	309	314	B-Organism
tumors	315	321	B-Pathological_formation
.	321	322	O

In	323	325	O
particular	326	336	O
,	336	337	O
the	338	341	O
activity	342	350	O
of	351	353	O
angiogenic	354	364	O
factors	365	372	O
is	373	375	O
crucial	376	383	O
for	384	387	O
tumor	388	393	B-Pathological_formation
progression	394	405	O
.	405	406	O

We	407	409	O
previously	410	420	O
characterized	421	434	O
a	435	436	O
secreted	437	445	O
fibroblast	446	456	B-Gene_or_gene_product
growth	457	463	I-Gene_or_gene_product
factor	464	470	I-Gene_or_gene_product
-	470	471	I-Gene_or_gene_product
binding	471	478	I-Gene_or_gene_product
protein	479	486	I-Gene_or_gene_product
(	487	488	O
FGF	488	491	B-Gene_or_gene_product
-	491	492	I-Gene_or_gene_product
BP	492	494	I-Gene_or_gene_product
)	494	495	O
as	496	498	O
a	499	500	O
chaperone	501	510	O
molecule	511	519	O
,	519	520	O
which	521	526	O
binds	527	532	O
to	533	535	O
various	536	543	O
FGFs	544	548	B-Gene_or_gene_product
,	548	549	O
enhances	550	558	O
FGF	559	562	B-Gene_or_gene_product
-	562	563	O
mediated	563	571	O
biochemical	572	583	O
and	584	587	O
biologic	588	596	O
events	597	603	O
and	604	607	O
importantly	608	619	O
is	620	622	O
a	623	624	O
crucial	625	632	O
rate	633	637	O
-	637	638	O
limiting	638	646	O
factor	647	653	O
for	654	657	O
tumor	658	663	B-Pathological_formation
-	663	664	O
dependent	664	673	O
angiogenesis	674	686	O
.	686	687	O

We	688	690	O
generated	691	700	O
monoclonal	701	711	O
antibodies	712	722	O
that	723	727	O
target	728	734	O
FGF	735	738	B-Gene_or_gene_product
-	738	739	I-Gene_or_gene_product
BP	739	741	I-Gene_or_gene_product
protein	742	749	O
and	750	753	O
used	754	758	O
them	759	763	O
as	764	766	O
a	767	768	O
tool	769	773	O
to	774	776	O
evaluate	777	785	O
frequency	786	795	O
and	796	799	O
pattern	800	807	O
of	808	810	O
FGF	811	814	B-Gene_or_gene_product
-	814	815	I-Gene_or_gene_product
BP	815	817	I-Gene_or_gene_product
expression	818	828	O
during	829	835	O
the	836	839	O
malignant	840	849	O
progression	850	861	O
of	862	864	O
pancreas	865	873	B-Pathological_formation
and	874	877	O
colorectal	878	888	B-Pathological_formation
carcinoma	889	898	I-Pathological_formation
in	899	901	O
archival	902	910	O
tissue	911	917	B-Tissue
samples	918	925	I-Tissue
.	925	926	O

We	927	929	O
found	930	935	O
that	936	940	O
FGF	941	944	B-Gene_or_gene_product
-	944	945	I-Gene_or_gene_product
BP	945	947	I-Gene_or_gene_product
is	948	950	O
dramatically	951	963	O
upregulated	964	975	O
during	976	982	O
the	983	986	O
initiation	987	997	O
of	998	1000	O
colorectal	1001	1011	B-Pathological_formation
and	1012	1015	O
pancreatic	1016	1026	B-Pathological_formation
adenocarcinoma	1027	1041	I-Pathological_formation
.	1041	1042	O

Crucial	1043	1050	O
genetic	1051	1058	O
events	1059	1065	O
underlying	1066	1076	O
the	1077	1080	O
initiation	1081	1091	O
and	1092	1095	O
progression	1096	1107	O
of	1108	1110	O
colorectal	1111	1121	B-Pathological_formation
and	1122	1125	O
pancreatic	1126	1136	B-Pathological_formation
adenocarcinoma	1137	1151	I-Pathological_formation
with	1152	1156	O
a	1157	1158	O
particular	1159	1169	O
focus	1170	1175	O
on	1176	1178	O
the	1179	1182	O
modulation	1183	1193	O
of	1194	1196	O
angiogenesis	1197	1209	O
and	1210	1213	O
antiangiogenic	1214	1228	O
therapies	1229	1238	O
are	1239	1242	O
discussed	1243	1252	O
.	1252	1253	O

We	1254	1256	O
propose	1257	1264	O
that	1265	1269	O
the	1270	1273	O
upregulation	1274	1286	O
of	1287	1289	O
the	1290	1293	O
secreted	1294	1302	O
FGF	1303	1306	B-Gene_or_gene_product
-	1306	1307	I-Gene_or_gene_product
BP	1307	1309	I-Gene_or_gene_product
protein	1310	1317	O
during	1318	1324	O
early	1325	1330	O
phases	1331	1337	O
of	1338	1340	O
pancreas	1341	1349	B-Pathological_formation
and	1350	1353	O
colon	1354	1359	B-Pathological_formation
cancer	1360	1366	I-Pathological_formation
could	1367	1372	O
make	1373	1377	O
this	1378	1382	O
protein	1383	1390	O
a	1391	1392	O
possible	1393	1401	O
serum	1402	1407	B-Organism_substance
marker	1408	1414	O
indicating	1415	1425	O
the	1426	1429	O
presence	1430	1438	O
of	1439	1441	O
high	1442	1446	B-Pathological_formation
-	1446	1447	I-Pathological_formation
risk	1447	1451	I-Pathological_formation
premalignant	1452	1464	I-Pathological_formation
lesions	1465	1472	I-Pathological_formation
.	1472	1473	O

Furthermore	1474	1485	O
,	1485	1486	O
the	1487	1490	O
biological	1491	1501	O
activity	1502	1510	O
of	1511	1513	O
FGF	1514	1517	B-Gene_or_gene_product
-	1517	1518	I-Gene_or_gene_product
BP	1518	1520	I-Gene_or_gene_product
is	1521	1523	O
neutralized	1524	1535	O
by	1536	1538	O
monoclonal	1539	1549	O
antibodies	1550	1560	O
suggesting	1561	1571	O
the	1572	1575	O
potential	1576	1585	O
for	1586	1589	O
antibody	1590	1598	O
-	1598	1599	O
based	1599	1604	O
therapeutic	1605	1616	O
targeting	1617	1626	O
.	1626	1627	O

